Salofalk with colitis
Salofalk is a non-steroidal anti-inflammatory drug.As an active ingredient in colitis, mesalazine appears, which suppresses the activity of neutrophilic lipoxygenase, as well as the onset of the formation of arachidonic acid metabolite, which is a proinflammatory mediator.It can inhibit lymphocyte secretion of immunoglobulins, and also has an effect on migration, phagocytosis and degranulation of neutrophilic granulocytes.Presence of antioxidant effects in colitis.
Salofalk in colitis, depending on the type of use that was used, will be released in the colon cavity and in the terminal section of the small intestine.It can also be released into the cavity of the rectum and colon.
Salofalk is used in case of detection of Crohn's disease and colitis of ulcerative form.Produced in several forms: tablets, granules, suppository and enema.To choose the place of administration of the drug, the duration of the affected intestinal tracts and the localization of pathological processes are determined.In combing
Suppositories in case of acute form of the disease are introduced into the rectal cavity at 500 mg 3 times a day.With a very pronounced form, the dosage is doubled.In the event that there will be a long treatment, it is recommended to use 250 mg 3 times a day.The period of therapy is 8-12 weeks.
The enema slurry is applied at a dosage of 60 g 1 time per day at bedtime after the intestinal pre-treatment was performed.
Before Salofalk is prescribed for colitis, and after 2 weeks of taking the doctor, a clinical blood test and a general urine test will be administered.The same survey program is conducted 4 weeks later several times.If good control results are shown, the survey is conducted once every 3 months.Periodically, a determination of the concentration of creatine and urea in blood serum is required.The urinary sediment is also examined.Use Salofalk in colitis need with extreme caution to those who have lung diseases with a violation of their functionality.